CytoMed Therapeutics Ltd — Form 4/A
Filed July 24, 2026 · analyzed by the Insider Agent
4/A
▲ Likely positive
significance 58/100
What the filing says
Director Choo Chee Kong (GDTC) bought 200K shares (~$300K) on the open market (24% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.